| Literature DB >> 19457692 |
Laila El Mansouri1, Tifenn Couchouron, Guillaume Le Roux, Catherine Dugast, Françoise Burtin, Jean-David Albert, Aleth Perdriger, Najia Hajjaj Hassouni, Gérard Chalès.
Abstract
A 72-year-old male with a 4-year history of TNFalpha antagonist therapy (infliximab and etanercept) for ankylosing spondylitis was diagnosed with breast cancer. He had a family history of breast cancer. The low incidence and considerable severity of breast cancer in males, genetic risk factors, and potential role for TNFalpha antagonist therapy are discussed.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19457692 DOI： 10.1016/j.jbspin.2008.12.004
Source DB: PubMed Journal: Joint Bone Spine ISSN： 1297-319X Impact factor: 4.929